chartexchange

Sutro Biopharma Announces First Patient Dosed in Phase 1 Trial of STRO-006, a Next-Generation ITGB6-Targeting ADC, in Advanced Solid Tumors

GlobeNewswire Inc. | Oct 21, 2026 8:00 AM EDT

— STRO-006 is Sutro’s second wholly-owned ADC to enter the clinic in less than one year —

Read original article